Pipeline

Constantly growing pipeline of product opportunities

EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.

 

Pipeline of product opportunities (including EVT Execute programmes)

Programme
Therapeutic area/Indication
Partner
Status
EVT201
CNS - Insomnia (GABA-A)
Jingxin
Phase II
BAY1817080
Chronic cough (P2X3)
Bayer
Phase II
BAYBUp
Chronic cough (P2X3)
Bayer
Phase II 
CT7001
Oncology (CDK7)
Carrick
Phase II
EVT401
Immunology & Inflammation (P2X7)
CONBA Group
Phase I
BAY1817080
Women's health - Endometriosis (P2X3)
Bayer
Phase I
BAYxxx
Women's health - Endometriosis (ND)
Bayer
Phase I
BAY2328065
Women's health - Endometriosis (ND)
Bayer
Phase I
BI 894416
Respiratory (ND)
Boehringer Ingelheim
Phase I
BI 860585
Oncology (mTORC1/2)
Boehringer Ingelheim/Xynomic Pharmaceuticals
Phase I
TPM203
Pemphigus Vulgaris (ND)
Topas Therapeutics
Phase I
DSP-1181
OCD (5-HT1A)
Exscientia
Phase I
CNTX 6016
Pain (CB2)
Boehringer Ingelheim
Phase I
EVT894
Chickungunya (ND)
Sanofi/NIH
Pre-clinical
BAYxxx
Women`s health - Endometriosis (ND)
Bayer
Pre-clinical
EVT801
Oncology (VEGFR3)
Sanofi
Pre-clinical
APN411
Oncology - Immunotherapy (ND)
Sanofi/Apeiron
Pre-clinical
QRB001
Diabetes - beta cell replacement therapy
Currently unpartnered
Pre-clinical
EXS21546
Oncology (ND)
Exscientia
Pre-clinical + several discovery programmes
GLPGxxx
Fibrosis (ND)
Galapagos
Pre-clinical
BMSxxx
Neurodegeneration (ND)
Bristol Myers Squibb
Pre-clinical
BAYxxx
Nephrology (ND)
Bayer
Pre-clinical
Various
CNS, Metabolic, Pain ......
>10 further programmes
Pre-clinical
Various
Nephrology
Bayer
Discovery
Various
Immunology & Inflammation
UCB
Discovery
Various
Neurodegeneration
Bristol-Myers Squibb
Discovery
Various
Oncology - solid tumours
Bristol-Myers Squibb
Discovery
Various
Immunology & Inflammation - Tissue Fibrosis
Pfizer
Discovery
TargetPicV
Antiviral
Bayer/Haplogen
Discovery
Various
Polycystic Ovary Syndrome 
Bayer/Celmatix
Discovery
ND
Dermatological diseases
Almirall
Discovery
ND
Oncology
Breakpoint Therapeutics
Discovery
ND
Anti-infectives
Forge Therapeutics
Discovery
ND
FSHD
Facio Therapies
Discovery
INDY inhibitor
Metabolic
Eternygen
Discovery
ND
Fibrotic disease
Fibrocor/Galapagos
Discovery
Various
Various
Topas Therapeutics
Discovery
Various
Various

LAB282 / LAB150 / LAB591 / LAB031 / LAB10x / LAB555

Discovery
Various
Anti-infectives
>5 programmes
Discovery
Various
Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
>40 further programmes
Discovery
Programme EVT201
Therapeutic area/Indication CNS - Insomnia (GABA-A)
Partner Jingxin
Status Phase II
Programme BAY1817080
Therapeutic area/Indication Chronic cough (P2X3)
Partner Bayer
Status Phase II
Programme BAYBUp
Therapeutic area/Indication Chronic cough (P2X3)
Partner Bayer
Status Phase II 
Programme CT7001
Therapeutic area/Indication Oncology (CDK7)
Partner Carrick
Status Phase II
Programme EVT401
Therapeutic area/Indication Immunology & Inflammation (P2X7)
Partner CONBA Group
Status Phase I
Programme BAY1817080
Therapeutic area/Indication Women's health - Endometriosis (P2X3)
Partner Bayer
Status Phase I
Programme BAYxxx
Therapeutic area/Indication Women's health - Endometriosis (ND)
Partner Bayer
Status Phase I
Programme BAY2328065
Therapeutic area/Indication Women's health - Endometriosis (ND)
Partner Bayer
Status Phase I
Programme BI 894416
Therapeutic area/Indication Respiratory (ND)
Partner Boehringer Ingelheim
Status Phase I
Programme BI 860585
Therapeutic area/Indication Oncology (mTORC1/2)
Partner Boehringer Ingelheim/Xynomic Pharmaceuticals
Status Phase I
Programme TPM203
Therapeutic area/Indication Pemphigus Vulgaris (ND)
Partner Topas Therapeutics
Status Phase I
Programme DSP-1181
Therapeutic area/Indication OCD (5-HT1A)
Partner Exscientia
Status Phase I
Programme CNTX 6016
Therapeutic area/Indication Pain (CB2)
Partner Boehringer Ingelheim
Status Phase I
Programme EVT894
Therapeutic area/Indication Chickungunya (ND)
Partner Sanofi/NIH
Status Pre-clinical
Programme BAYxxx
Therapeutic area/Indication Women`s health - Endometriosis (ND)
Partner Bayer
Status Pre-clinical
Programme EVT801
Therapeutic area/Indication Oncology (VEGFR3)
Partner Sanofi
Status Pre-clinical
Programme APN411
Therapeutic area/Indication Oncology - Immunotherapy (ND)
Partner Sanofi/Apeiron
Status Pre-clinical
Programme QRB001
Therapeutic area/Indication Diabetes - beta cell replacement therapy
Partner Currently unpartnered
Status Pre-clinical
Programme EXS21546
Therapeutic area/Indication Oncology (ND)
Partner Exscientia
Status Pre-clinical + several discovery programmes
Programme GLPGxxx
Therapeutic area/Indication Fibrosis (ND)
Partner Galapagos
Status Pre-clinical
Programme BMSxxx
Therapeutic area/Indication Neurodegeneration (ND)
Partner Bristol Myers Squibb
Status Pre-clinical
Programme BAYxxx
Therapeutic area/Indication Nephrology (ND)
Partner Bayer
Status Pre-clinical
Programme Various
Therapeutic area/Indication CNS, Metabolic, Pain ......
Partner >10 further programmes
Status Pre-clinical
Programme Various
Therapeutic area/Indication Nephrology
Partner Bayer
Status Discovery
Programme Various
Therapeutic area/Indication Immunology & Inflammation
Partner UCB
Status Discovery
Programme Various
Therapeutic area/Indication Neurodegeneration
Partner Bristol-Myers Squibb
Status Discovery
Programme Various
Therapeutic area/Indication Oncology - solid tumours
Partner Bristol-Myers Squibb
Status Discovery
Programme Various
Therapeutic area/Indication Immunology & Inflammation - Tissue Fibrosis
Partner Pfizer
Status Discovery
Programme TargetPicV
Therapeutic area/Indication Antiviral
Partner Bayer/Haplogen
Status Discovery
Programme Various
Therapeutic area/Indication Polycystic Ovary Syndrome 
Partner Bayer/Celmatix
Status Discovery
Programme ND
Therapeutic area/Indication Dermatological diseases
Partner Almirall
Status Discovery
Programme ND
Therapeutic area/Indication Oncology
Partner Breakpoint Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication Anti-infectives
Partner Forge Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication FSHD
Partner Facio Therapies
Status Discovery
Programme INDY inhibitor
Therapeutic area/Indication Metabolic
Partner Eternygen
Status Discovery
Programme ND
Therapeutic area/Indication Fibrotic disease
Partner Fibrocor/Galapagos
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner Topas Therapeutics
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner

LAB282 / LAB150 / LAB591 / LAB031 / LAB10x / LAB555

Status Discovery
Programme Various
Therapeutic area/Indication Anti-infectives
Partner >5 programmes
Status Discovery
Programme Various
Therapeutic area/Indication Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
Partner >40 further programmes
Status Discovery

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 vCard
TOP